Kyntra Bio, Inc. (KYNB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyntra Bio, Inc. (KYNB) has a cash flow conversion efficiency ratio of 0.451x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.89 Million) by net assets ($-30.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View today's stock price for Kyntra Bio, Inc. for real-time trading data and today's change.
Kyntra Bio, Inc. - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Kyntra Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see KYNB stock market capitalisation for the company's overall valuation and market capitalisation.
Kyntra Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyntra Bio, Inc. ranked by their cash flow conversion efficiency. Also see Kyntra Bio, Inc. balance sheet assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Franklin Wireless Corp
NASDAQ:FKWL
|
0.000x |
|
Lyka Labs Limited
NSE:LYKALABS
|
0.135x |
|
Kincora Copper Ltd
V:KCC
|
-0.005x |
|
Touch Ventures Ltd
AU:TVL
|
0.006x |
|
Katapult Holdings Inc
NASDAQ:KPLT
|
0.748x |
|
IDENTILLECT TECHN. O.N.
F:8ID
|
N/A |
|
Gencurix Inc
KQ:229000
|
-0.094x |
|
BayWa Aktiengesellschaft
F:BYW
|
-0.099x |
Annual Cash Flow Conversion Efficiency for Kyntra Bio, Inc. (2012–2025)
The table below shows the annual cash flow conversion efficiency of Kyntra Bio, Inc. from 2012 to 2025. Review Kyntra Bio, Inc. (KYNB) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.47 Million | $-4.77 Million | -1.067x | -241.96% |
| 2024-12-31 | $-183.63 Million | $-138.00 Million | 0.751x | -61.31% |
| 2023-12-31 | $-162.20 Million | $-315.02 Million | 1.942x | -98.03% |
| 2022-12-31 | $-1.48 Million | $-145.93 Million | 98.603x | +27572.66% |
| 2021-12-31 | $229.11 Million | $-82.23 Million | -0.359x | -294.16% |
| 2020-12-31 | $441.45 Million | $81.60 Million | 0.185x | +225.75% |
| 2019-12-31 | $535.41 Million | $-78.70 Million | -0.147x | -2.02% |
| 2018-12-31 | $528.47 Million | $-76.14 Million | -0.144x | -26.17% |
| 2017-12-31 | $582.45 Million | $-66.51 Million | -0.114x | -381.33% |
| 2016-12-31 | $175.11 Million | $7.11 Million | 0.041x | +143.02% |
| 2015-12-31 | $196.82 Million | $-18.57 Million | -0.094x | -201.31% |
| 2014-12-31 | $240.68 Million | $22.41 Million | 0.093x | -61.34% |
| 2013-12-31 | $107.60 Million | $25.92 Million | 0.241x | +625.07% |
| 2012-12-31 | $122.18 Million | $-5.61 Million | -0.046x | -- |
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible fact… Read more